Clinical Trials Logo

Clinical Trial Summary

This is a single-arm, open-label, dose-escalation study to explore the safety, efficacy, and cytodynamic characteristics of the drug, and to initially observe the efficacy of the drug in subjects with relapsed/refractory B7-H3-positive acute myeloid cell line leukemia.


Clinical Trial Description

Eligible subjects will receive 1.0×10^8 CAR gdT, 2.0×10^8 CAR gdT, 4.0×10^8 CAR gdT, or additional doses may be added at the discretion of investigator and sponsor. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05722171
Study type Interventional
Source PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Contact Heng Mei, Doctor
Phone +86-13886160811
Email mayheng@126.com
Status Recruiting
Phase Early Phase 1
Start date December 27, 2022
Completion date December 27, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05731219 - UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT05061147 - A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Phase 1/Phase 2
Not yet recruiting NCT05548088 - LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Terminated NCT03504410 - Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML Phase 3
Enrolling by invitation NCT05332054 - Long-Term Follow-up Study
Withdrawn NCT03904069 - Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML Phase 1
Completed NCT05518357 - LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT03190278 - Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Completed NCT02665143 - A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia Phase 2
Completed NCT03886831 - A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies Phase 1
Completed NCT03318016 - Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT06084819 - Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Phase 2
No longer available NCT05627466 - US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia